A significant advancement in knowledge of the link between cognition and genetics has been made thanks to a study led by ...

Holding released a new polygenic risk score report on the genetics of osteoporosis for 23andMe+ Premium members. The report ...

The latest unsurprising development in 23andMe’s story is the admission, by their new board of directors, that 23andMe now does not have enough cash to continue for the next 12 months. They are now ...

The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million. © 2024 TechCrunch. All rights reserved. For personal use only.

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.